March 2, 2020 / 12:49 PM / a month ago

BRIEF-Karyopharm Announces Phase 3 Boston Study Meets Primary Endpoint

March 2 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM ANNOUNCES PHASE 3 BOSTON STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT INCREASE IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA FOLLOWING ONE TO THREE PRIOR LINES OF THERAPY

* KARYOPHARM THERAPEUTICS INC - REGULATORY SUBMISSION PLANNED IN 2Q 2020; DATA TO BE SUBMITTED FOR PRESENTATION AT UPCOMING MEDICAL MEETINGS

* KARYOPHARM THERAPEUTICS INC - 47% INCREASE IN MEDIAN PFS ON SVD VERSUS VD

* KARYOPHARM THERAPEUTICS INC - BOSTON STUDY MET ITS PRIMARY ENDPOINT OF A STATISTICALLY SIGNIFICANT INCREASE IN PROGRESSION-FREE SURVIVAL

* KARYOPHARM THERAPEUTICS INC - THERE WERE NO NEW SAFETY SIGNALS ON SVD ARM AND THERE WAS NO IMBALANCE IN DEATHS BETWEEN TWO ARMS IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below